Krebs Biochem

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 05-Sep, Krebs Biochemicals & Industries Ltd's stock price is Rs 56.00, up 7.44% today. However, it has a year-to-date decline of 19.59% and faces challenges with declining investor participation.

As of 05-Sep, Krebs Biochemicals & Industries Ltd is experiencing a rise in its stock price, currently at Rs 56.00, reflecting a change of Rs 3.88 or 7.44% increase. This upward movement is supported by the stock outperforming its sector by 7.89% today and opening with a gain of 7.21%. Additionally, the stock reached an intraday high of Rs 56.22, indicating strong trading activity within the day.<BR><BR>Despite this positive performance today, it is important to note that the stock has shown a negative trend over longer periods, with a year-to-date decline of 19.59% and a one-year decline of 22.94%. Furthermore, the stock has been trading erratically, having not traded on one day out of the last 20 days, and there has been a decrease in investor participation, as evidenced by a 3.74% drop in delivery volume compared to the five-day average.<BR><BR>Overall, while Krebs Biochemicals & Industries Ltd is currently rising in price, it faces challenges from its historical performance and declining investor participation.

Which are the latest news on Krebs Biochem?

Who are in the management team of Krebs Biochem?

The management team of Krebs Biochem includes G V L Prasad (Independent Director), R T Ravi (Chairman), Avinash Ravi (Non-Executive Director), Tangirala Malati, Satish Khivsara, Raj Kamal Prasad Verma (all Independent Directors), Rohit Taparia (Company Secretary), and Jitendra Shah (Managing Director). This diverse team brings a wide range of expertise to the company.

The management team of Krebs Biochem includes the following individuals:<BR><BR>1. **G V L Prasad** - Independent Director<BR>2. **R T Ravi** - Chairman (Non-Executive)<BR>3. **Avinash Ravi** - Non-Executive Director<BR>4. **Tangirala Malati** - Independent Director<BR>5. **Satish Khivsara** - Independent Director<BR>6. **Raj Kamal Prasad Verma** - Independent Director<BR>7. **Rohit Taparia** - Company Secretary & Compliance Officer<BR>8. **Jitendra Shah** - Managing Director<BR><BR>This team brings a diverse range of expertise to the company. If you have any more questions about Krebs Biochem or its operations, feel free to ask!

What does Krebs Biochem do?

Krebs Biochemicals & Industries Ltd manufactures Active Pharmaceutical Ingredients (API) through fermentation processes and operates in the Pharmaceuticals & Biotechnology industry. As of June 2026, it reported net sales of 7 Cr and a net loss of 2 Cr, with a market cap of INR 121 Cr.

Overview: <BR>Krebs Biochemicals & Industries Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) through fermentation processes, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1991, Krebs Biochemicals & Industries Ltd was promoted by R T Ravi. The company was formerly known as Krebs Biochemicals Ltd. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 121 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.38 <BR>Return on Equity: 8.66% <BR>Price to Book: -0.77 <BR><BR>Contact Details: <BR>Address: Kothapalli(V) Kasimkota(M), Anakapalli Vishakapatnam Andhra Pradesh : 531031 <BR>Tel: 91-040-6680 8040 <BR>Email: investors@kerbsbiochem.com <BR>Website: http://www.krebsbiochem.com

Who are the peers of the Krebs Biochem?

Krebs Biochem's peers include Lactose (India), Bal Pharma, Alpa Laboratorie, Kimia Bioscien., Makers Labs., Tyche Industries, Pharmaids Pharma, Godavari Drugs, and Balaxi Pharma. In terms of performance, Krebs Biochem has a 1-year return of -22.27%, higher than Alpa Laboratorie's -33.56% but lower than Makers Labs.'s 25.01%.

Peers: Krebs Biochem's peers include Lactose (India), Bal Pharma, Alpa Laboratorie, Kimia Bioscien., Makers Labs., Tyche Industries, Pharmaids Pharma, Godavari Drugs, and Balaxi Pharma.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lactose (India), Kimia Bioscien., Makers Labs., Pharmaids Pharma, and the rest. Average management risk is found at Bal Pharma, Alpa Laboratorie, Tyche Industries, Godavari Drugs, Balaxi Pharma, and the rest. Krebs Biochem does not qualify for management risk assessment. Growth is rated as Good for Lactose (India), while Average growth is noted for Pharmaids Pharma, and the rest. Below Average growth is seen at Bal Pharma, Alpa Laboratorie, Kimia Bioscien., Makers Labs., Tyche Industries, Godavari Drugs, and the rest. Krebs Biochem does not qualify for growth assessment. Capital Structure is rated as Excellent for Tyche Industries and Balaxi Pharma, while Good capital structure is observed at Alpa Laboratorie, and the rest. Below Average capital structure is noted for Lactose (India), Bal Pharma, Kimia Bioscien., Makers Labs., Pharmaids Pharma, Godavari Drugs, and the rest. Krebs Biochem does not qualify for capital structure assessment.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Makers Labs. at 25.01%, while the peer with the lowest is Alpa Laboratorie at -33.56%. Krebs Biochem's 1-year return is -22.27%, which is higher than Alpa Laboratorie's but lower than Makers Labs. Additionally, the peers with negative six-month returns include Tyche Industries, Pharmaids Pharma, and Kimia Bioscien.

How big is Krebs Biochem?

As of 31st August, Krebs Biochemicals & Industries Ltd has a market capitalization of 121.00 Cr and reported Net Sales of 25.23 Cr with a Net Profit loss of 14.09 Cr over the latest four quarters. Shareholder's Funds are at a loss of 146.24 Cr, while Total Assets are 169.04 Cr.

As of 31st August, Krebs Biochemicals & Industries Ltd has a market capitalization of 121.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Krebs Biochem reported Net Sales of 25.23 Cr. However, the company experienced a loss of 14.09 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds are reported at a loss of 146.24 Cr, while Total Assets stand at 169.04 Cr.

Should I buy, sell or hold Krebs Biochemicals & Industries Ltd?

Are Krebs Biochemicals & Industries Ltd latest results good or bad?

Krebs Biochemicals & Industries Ltd's latest results are concerning, showing a net loss of ₹2.34 crores and ongoing operational challenges, despite a slight increase in net sales. The company has negative equity and has recorded losses for seven consecutive quarters, indicating a struggling financial position.

Krebs Biochemicals & Industries Ltd's latest results indicate a challenging financial situation. In the fourth quarter of FY26, the company reported a net loss of ₹2.34 crores, which, while an improvement of 25.24% from the previous quarter, is still significantly worse than the loss of ₹8.27 crores in the same quarter last year. The company's net sales of ₹6.81 crores showed a modest year-on-year growth of 11.64%, but this was accompanied by a sequential decline of 6.33% from the previous quarter.<BR><BR>The company's financial health is concerning, highlighted by a negative book value of ₹-67.83 per share and a persistent negative PAT margin of -34.36%. This reflects ongoing operational challenges and a lack of profitability, as the company has recorded losses for seven consecutive quarters. Additionally, the cash burn remains significant, with negative cash flow from operations reported in four of the last five years.<BR><BR>Overall, while there are some signs of improvement in sales growth, the fundamental issues of negative equity, persistent losses, and operational instability suggest that the results are more indicative of a struggling business rather than a turnaround. Investors should approach this company with caution given the current financial metrics and outlook.

When is the next results date for Krebs Biochemicals & Industries Ltd?

The next results date for Krebs Biochemicals & Industries Ltd is 21 May 2026.

The next results date for Krebs Biochemicals & Industries Ltd is scheduled for 21 May 2026.

How has been the historical performance of Krebs Biochem?

Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.

Answer:<BR>The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar'21 to 169.04 Cr in Mar'25, while shareholder's funds have deteriorated, showing a negative value of -146.24 Cr in Mar'25. The cash flow from operating activities has remained negative, indicating ongoing financial challenges. Overall, Krebs Biochem's financial performance has been characterized by declining revenues, increasing losses, and deteriorating equity over the years.

What is the technical trend for Krebs Biochem?

As of June 6, 2025, Krebs Biochem's technical trend has shifted to mildly bullish, supported by positive weekly MACD, KST, and Bollinger Bands, although daily moving averages suggest caution.

As of 6 June 2025, the technical trend for Krebs Biochem has changed from mildly bearish to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive shift in sentiment. The Bollinger Bands are also indicating a bullish stance on both weekly and monthly time frames. However, the daily moving averages remain mildly bearish, which suggests some caution. The Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly outlook. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands.

Who are the top shareholders of the Krebs Biochem?

The top shareholders of Krebs Biochem are Ipca Laboratories Limited, holding 49.65%, and Sun Pharmaceutical Industries Ltd, the largest public shareholder with 4.81%. Individual investors own 20.42%, while foreign institutional investors hold 0.5%, and there are no mutual funds invested in the company.

The top shareholders of Krebs Biochem include its majority shareholders, who are the promoters. The promoter with the highest holding is Ipca Laboratories Limited, which owns 49.65% of the company. Additionally, Sun Pharmaceutical Industries Ltd is the highest public shareholder, holding 4.81%. Individual investors collectively hold 20.42% of the shares, while foreign institutional investors (FIIs) hold 0.5% through five different FIIs. There are no mutual funds currently invested in Krebs Biochem.

Has Krebs Biochem declared dividend?

No Dividend History Available